See more : Uchida Yoko Co., Ltd. (8057.T) Income Statement Analysis – Financial Results
Complete financial analysis of Affimed N.V. (0HL9.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Affimed N.V., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- BeMetals Corp. (BMTLF) Income Statement Analysis – Financial Results
- Overstock.com, Inc. (OSTKO) Income Statement Analysis – Financial Results
- Mdundo.com A/S (MDUNDO.CO) Income Statement Analysis – Financial Results
- Manulife Financial Corp (MFC-PM.TO) Income Statement Analysis – Financial Results
- IBI Group Inc. (IBG.TO) Income Statement Analysis – Financial Results
Affimed N.V. (0HL9.L)
About Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.28M | 41.35M | 40.37M | 28.36M | 21.39M | 23.74M | 2.01M | 6.31M | 7.56M | 3.38M | 5.09M | 1.17M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.28M | 41.35M | 40.37M | 28.36M | 21.39M | 23.74M | 2.01M | 6.31M | 7.56M | 3.38M | 5.09M | 1.17M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 94.96M | 98.81M | 81.49M | 49.99M | 43.79M | 35.15M | 21.49M | 30.18M | 22.01M | 9.60M | 14.35M | 8.73M |
| General & Administrative | 24.68M | 32.08M | 24.22M | 13.72M | 10.27M | 9.64M | 7.99M | 8.32M | 7.55M | 2.35M | 7.05M | 3.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.68M | 32.08M | 24.22M | 13.72M | 10.27M | 9.64M | 7.99M | 8.32M | 7.55M | 2.35M | 7.05M | 3.05M |
| Other Expenses | -4.70M | 1.42M | 1.31M | 626.00K | -19.00K | 1.52M | 205.00K | 145.00K | 651.00K | 381.00K | 610.00K | 206.00K |
| Operating Expenses | 114.94M | 130.89M | 105.71M | 63.70M | 54.04M | 44.79M | 29.48M | 38.50M | 29.56M | 11.94M | 21.40M | 11.78M |
| Cost & Expenses | 114.94M | 130.89M | 105.71M | 63.70M | 54.04M | 44.79M | 29.48M | 38.50M | 29.56M | 11.94M | 21.40M | 11.78M |
| Interest Income | 509.00K | 361.00K | -415.00K | 186.00K | 602.00K | 5.00K | 77.00K | 122.00K | -1.00K | -3.00K | 9.00K | 3.00K |
| Interest Expense | 1.81M | 1.63M | 712.00K | 95.00K | 483.00K | 847.00K | 690.00K | 803.00K | 703.00K | 4.28M | 10.41M | 3.93M |
| Depreciation & Amortization | 1.75M | 2.85M | 1.39M | 1.04M | 903.38K | 415.90K | 329.70K | 387.00K | 336.00K | 441.00K | 427.00K | 408.00K |
| EBITDA | -102.38M | -81.47M | -64.01M | -34.23M | -30.97M | -18.88M | -27.26M | -31.10M | -19.20M | -8.12M | -15.27M | -9.99M |
| EBITDA Ratio | -1,237.22% | -209.51% | -158.56% | -120.69% | -145.15% | -79.53% | -1,348.96% | -503.96% | -286.41% | -240.04% | -300.12% | -851.32% |
| Operating Income | -106.66M | -88.12M | -64.03M | -34.72M | -32.38M | -19.54M | -27.26M | -32.04M | -21.34M | -8.18M | -15.70M | -10.40M |
| Operating Income Ratio | -1,288.95% | -213.09% | -158.62% | -122.42% | -151.35% | -82.31% | -1,356.22% | -507.51% | -282.24% | -241.81% | -308.69% | -886.36% |
| Total Other Income/Expenses | 726.00K | 2.12M | 6.51M | -6.65M | 15.00K | 60.00K | -2.98M | -230.00K | 1.10M | -416.82K | -10.40M | -3.93M |
| Income Before Tax | -105.94M | -86.00M | -57.52M | -41.37M | -32.36M | -19.48M | -30.24M | -32.27M | -20.24M | -425.00K | -26.10M | -14.32M |
| Income Before Tax Ratio | -1,280.18% | -207.97% | -142.50% | -145.86% | -151.28% | -82.06% | -1,504.63% | -511.15% | -267.64% | -12.57% | -513.07% | -1,221.06% |
| Income Tax Expense | 3.00K | 2.00K | 2.00K | 1.00K | 4.00K | 1.00K | -20.00K | -58.00K | -21.34M | -166.00K | -1.00K | -9.00K |
| Net Income | -105.94M | -86.00M | -57.52M | -41.37M | -32.37M | -19.48M | -30.22M | -32.22M | -20.24M | -259.00K | -26.10M | -14.31M |
| Net Income Ratio | -1,280.22% | -207.98% | -142.50% | -145.86% | -151.30% | -82.06% | -1,503.63% | -510.23% | -267.64% | -7.66% | -513.05% | -1,220.29% |
| EPS | -7.09 | -6.04 | -4.81 | -4.96 | -5.04 | -3.22 | -6.91 | -9.70 | -7.11 | -0.10 | -10.88 | -5.97 |
| EPS Diluted | -7.09 | -6.04 | -4.81 | -4.96 | -5.04 | -3.22 | -6.91 | -9.70 | -7.10 | -0.10 | -10.88 | -5.97 |
| Weighted Avg Shares Out | 14.94M | 14.24M | 11.95M | 8.35M | 6.42M | 6.05M | 4.37M | 3.32M | 2.85M | 2.59M | 2.40M | 2.40M |
| Weighted Avg Shares Out (Dil) | 14.94M | 14.24M | 11.95M | 8.35M | 6.42M | 6.05M | 4.37M | 3.32M | 2.85M | 2.59M | 2.40M | 2.40M |
Source: https://incomestatements.info
Category: Stock Reports